Online inquiry

IVTScrip™ mRNA-Anti-ICAM1, BI-505(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ4120MR)

This product GTTS-WQ4120MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets ICAM1 gene. The antibody can be applied in Multiple myeloma (MM) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_000201.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3383
UniProt ID P05362
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ICAM1, BI-505(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ4120MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ12149MR IVTScrip™ mRNA-Anti-CD248, MORAb-004(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA MORAb-004
GTTS-WQ7968MR IVTScrip™ mRNA-Anti-IL7R, GX-17(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA GX-17
GTTS-WQ7944MR IVTScrip™ mRNA-Anti-ICOS, GSK-3359609(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA GSK-3359609
GTTS-WQ13166MR IVTScrip™ mRNA-Anti-TNFRSF4, PF-04518600(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA PF-04518600
GTTS-WQ11848MR IVTScrip™ mRNA-Anti-TIGIT, MK-7684(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA MK-7684
GTTS-WQ1460MR IVTScrip™ mRNA-Anti-CD22, ACD22-VCMMAE(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ACD22-VCMMAE
GTTS-WQ10772MR IVTScrip™ mRNA-Anti-FGFR4, M-70(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA M-70
GTTS-WQ4639MR IVTScrip™ mRNA-Anti-LAG3, BMS-986016(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA BMS-986016
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW